Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Elwyn Loh"'
Autor:
Jennifer L. Gansert, Li Chen, Scott D. Patterson, Elwyn Loh, Charles S. Fuchs, Hedy L. Kindler, Sunita Badola, Samuel Suzuki, Rui Tang, Hongjie Deng, Yanyan Tudor, Ian McCaffery
PDF - 35K, Circulating biomarker distribution across arms.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb463da0a7b5c5c3046cd3d7eed8be83
https://doi.org/10.1158/1078-0432.22449972
https://doi.org/10.1158/1078-0432.22449972
Autor:
Josep Tabernero, Dominic Smethurst, Elwyn Loh, Jennifer Gansert, Lisa Chen, Kelly S. Oliner, Ian McCaffery, Rui Tang, Hongjie Deng, Hans Prenen, Elena Elez, Joe Stephenson, Irina Davidenko, Edith Mitchell, Niall C. Tebbutt, Anna Świeboda-Sadlej, Elzbieta Nowara, Cathy Eng, Eric Van Cutsem
PDF file - 22K, Supplemental Fig. S3. Effect of cytoplasmic MET immunohistochemistry (IHC) staining on objective response rate in patients treated with panitumumab (pmab) plus rilotumumab (AMG 102) versus pmab plus placebo.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::579be5694b8dcf083a41430c5de24fa7
https://doi.org/10.1158/1078-0432.22447464.v1
https://doi.org/10.1158/1078-0432.22447464.v1
Autor:
Jennifer L. Gansert, Li Chen, Scott D. Patterson, Elwyn Loh, Charles S. Fuchs, Hedy L. Kindler, Sunita Badola, Samuel Suzuki, Rui Tang, Hongjie Deng, Yanyan Tudor, Ian McCaffery
PDF - 43K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72536aebb5d957132158f52805e94e3d
https://doi.org/10.1158/1078-0432.22449966.v1
https://doi.org/10.1158/1078-0432.22449966.v1
Autor:
Josep Tabernero, Dominic Smethurst, Elwyn Loh, Jennifer Gansert, Lisa Chen, Kelly S. Oliner, Ian McCaffery, Rui Tang, Hongjie Deng, Hans Prenen, Elena Elez, Joe Stephenson, Irina Davidenko, Edith Mitchell, Niall C. Tebbutt, Anna Świeboda-Sadlej, Elzbieta Nowara, Cathy Eng, Eric Van Cutsem
PDF file - 37K, Supplemental Fig. S4. The effect of baseline IGF and IGF-related protein expression on overall survival.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fa54745b1bd504f4572d41f9069c652
https://doi.org/10.1158/1078-0432.22447461.v1
https://doi.org/10.1158/1078-0432.22447461.v1
Autor:
Jennifer L. Gansert, Li Chen, Scott D. Patterson, Elwyn Loh, Charles S. Fuchs, Hedy L. Kindler, Sunita Badola, Samuel Suzuki, Rui Tang, Hongjie Deng, Yanyan Tudor, Ian McCaffery
PDF - 74K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29ce111c7b0455722493d6fd8103c6ba
https://doi.org/10.1158/1078-0432.22449960
https://doi.org/10.1158/1078-0432.22449960
Autor:
Josep Tabernero, Dominic Smethurst, Elwyn Loh, Jennifer Gansert, Lisa Chen, Kelly S. Oliner, Ian McCaffery, Rui Tang, Hongjie Deng, Hans Prenen, Elena Elez, Joe Stephenson, Irina Davidenko, Edith Mitchell, Niall C. Tebbutt, Anna Świeboda-Sadlej, Elzbieta Nowara, Cathy Eng, Eric Van Cutsem
PDF file - 76K, Supplemental Fig. S1. (A) Randomized phase Ib/II trial of panitumumab plus rilotumumab (AMG 102) or ganitumab (AMG 479). (B) CONSORT diagram for part 2. *Panitumumab 6 mg/kg; rilotumumab 10 mg/kg with dose de-escalation to 5 mg/kg as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87a99d014edea26951bac27336d2db7f
https://doi.org/10.1158/1078-0432.22447470.v1
https://doi.org/10.1158/1078-0432.22447470.v1
Autor:
Winald R. Gerritsen, Sarita Dubey, Elwyn Loh, Yizhou Jiang, Kelly S. Oliner, Rui Tang, Min Zhu, Sandy Srinivas, Jean-Pascal Machiels, Frédéric Forget, Karim Fizazi, Gwenaëlle Gravis, Joel Picus, Joshi Alumkal, Siobhan Ng, Mark Rosenthal, Charles J. Ryan
PDF file - 883K, Patient disposition by treatment group. IP, investigational product; MP, mitoxantrone and prednisone. *Patient had a decrease in hemoglobin prior to administration of IP on day 1 of cycle 1. �Patient had delays to cycles prior to c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37edf82e35ba58776afcdc674fe3048a
https://doi.org/10.1158/1078-0432.22446554
https://doi.org/10.1158/1078-0432.22446554
Autor:
Josep Tabernero, Dominic Smethurst, Elwyn Loh, Jennifer Gansert, Lisa Chen, Kelly S. Oliner, Ian McCaffery, Rui Tang, Hongjie Deng, Hans Prenen, Elena Elez, Joe Stephenson, Irina Davidenko, Edith Mitchell, Niall C. Tebbutt, Anna Świeboda-Sadlej, Elzbieta Nowara, Cathy Eng, Eric Van Cutsem
PDF file - 38K, Supplemental Fig. S5. The effect of baseline IGF and IGF-related protein expression on objective response rate.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::273b680cc3bdef871af4b840596e44f1
https://doi.org/10.1158/1078-0432.22447458
https://doi.org/10.1158/1078-0432.22447458
Autor:
Josep Tabernero, Dominic Smethurst, Elwyn Loh, Jennifer Gansert, Lisa Chen, Kelly S. Oliner, Ian McCaffery, Rui Tang, Hongjie Deng, Hans Prenen, Elena Elez, Joe Stephenson, Irina Davidenko, Edith Mitchell, Niall C. Tebbutt, Anna Świeboda-Sadlej, Elzbieta Nowara, Cathy Eng, Eric Van Cutsem
PDF file - 38K, Supplemental Fig. S2. Best percent change of the sum of longest diameters of target lesions from baseline to post-baseline. (A) Panitumumab plus rilotumumab.(B) Panitumumab plus ganitumab. (C) Panitumumab alone.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7baaa18fa476f138cb3e2f19e8234f5c
https://doi.org/10.1158/1078-0432.22447467
https://doi.org/10.1158/1078-0432.22447467
Autor:
Juan Jose Perez Ruixo, Elwyn Loh, Kelly S. Oliner, Min Zhu, Yilong Zhang, Per Olsson Gisleskog, Sameer Doshi
Purpose: Rilotumumab is an investigational, fully human monoclonal antibody to hepatocyte growth factor. In a randomized phase II study, trends toward improved survival were observed with rilotumumab (7.5 or 15 mg/kg) plus epirubicin, cisplatin, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afbc014c10fbb12c551db4508bace707
https://doi.org/10.1158/1078-0432.c.6524000
https://doi.org/10.1158/1078-0432.c.6524000